Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down to $91.18

Viking Therapeutics, Inc. (NASDAQ:VKTXGet Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $91.18, but opened at $79.59. Viking Therapeutics shares last traded at $78.78, with a volume of 6,364,133 shares trading hands.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Jefferies Financial Group initiated coverage on shares of Viking Therapeutics in a research note on Thursday. They set a “buy” rating and a $110.00 price objective on the stock. Stifel Nicolaus lifted their price target on shares of Viking Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. William Blair restated an “outperform” rating on shares of Viking Therapeutics in a research report on Friday, February 23rd. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research report on Friday, February 9th. Finally, Oppenheimer raised their price objective on shares of Viking Therapeutics from $46.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Viking Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $76.22.

View Our Latest Stock Report on VKTX

Viking Therapeutics Stock Performance

The business’s 50 day simple moving average is $36.11 and its 200-day simple moving average is $21.25.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last issued its earnings results on Wednesday, February 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). During the same quarter last year, the business posted ($0.26) EPS. Equities research analysts expect that Viking Therapeutics, Inc. will post -1.11 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Brian Lian sold 269,079 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $26.87, for a total transaction of $7,230,152.73. Following the transaction, the chief executive officer now owns 2,184,882 shares in the company, valued at approximately $58,707,779.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Brian Lian sold 269,079 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $26.87, for a total transaction of $7,230,152.73. Following the transaction, the chief executive officer now owns 2,184,882 shares in the company, valued at approximately $58,707,779.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sarah Kathryn Rouan sold 30,000 shares of the firm’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $23.05, for a total transaction of $691,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 374,079 shares of company stock worth $9,729,653. 4.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VKTX. Retirement Group LLC boosted its holdings in Viking Therapeutics by 75.0% during the second quarter. Retirement Group LLC now owns 2,100 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 900 shares during the period. Cetera Advisor Networks LLC bought a new stake in Viking Therapeutics during the 2nd quarter valued at approximately $36,000. Wetzel Investment Advisors Inc. acquired a new stake in Viking Therapeutics in the 4th quarter valued at approximately $37,000. Engineers Gate Manager LP bought a new position in Viking Therapeutics in the 1st quarter worth approximately $37,000. Finally, US Bancorp DE increased its position in Viking Therapeutics by 66.5% in the 4th quarter. US Bancorp DE now owns 2,346 shares of the biotechnology company’s stock worth $44,000 after buying an additional 937 shares during the period. Institutional investors own 78.13% of the company’s stock.

Viking Therapeutics Company Profile

(Get Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

See Also

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.